CIC-39Na 逆转管状聚集性肌病特征性血小板减少
管状聚集性肌病由 STIM1/ORAI1 功能获得性突变引起,STIM1 p.I115F 小鼠模型再现肌无力和血小板减少。本研究发现钙库操作性钙内流抑制剂 CIC-39Na 可恢复该小鼠血小板数量并纠正异常出血,主要机制与血小板清除和血小板胞质基础钙水平恢复有关。
要点
- STIM1 p.I115F 小鼠再现管状聚集性肌病的肌无力和血小板减少。
- CIC-39Na 恢复 STIM1 p.I115F 小鼠血小板数量并纠正异常出血。
- 野生型与 STIM1 p.I115F 小鼠的主要差异在血小板清除和血小板胞质基础钙水平,CIC-39Na 使两者恢复。
核心结论
- CIC-39Na 可恢复 STIM1 p.I115F 小鼠血小板数量并纠正异常出血,为管状聚集性肌病患者血小板减少的药理学治疗策略开辟道路。
研究设计与样本
- 研究使用携带 STIM1 p.I115F 突变的小鼠模型,该模型再现 STIM1 功能获得性障碍的主要特征:肌无力和血小板减少。
- 原文未报告样本量、分组数及给药方案。
主要发现
- STIM1 p.I115F 小鼠中观察到血小板生成存在细微差异。
- 野生型与 STIM1 p.I115F 小鼠的主要差异在于血小板清除和血小板胞质基础钙水平。
- 使用 CIC-39Na 治疗后,血小板清除和血小板胞质基础钙水平均恢复。
临床怎么用
- 原文结论指出该发现为管状聚集性肌病患者血小板减少的药理学治疗策略开辟道路。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Store-operated Ca2+-entry is a cellular mechanism that governs the replenishment of intracellular stores of Ca2+ upon depletion caused by the opening of intracellular Ca2+-channels. Gain-of-function mutations of the 2 key proteins of store-operated Ca2+-entry, STIM1 and ORAI1, are associated with several ultra-rare diseases clustered as tubular aggregate myopathies. Our group has previously demonstrated that a mouse model bearing the STIM1 p.I115F mutation recapitulates the main features of the STIM1 gain-of-function disorders: muscle weakness and thrombocytopenia. Similar findings have been found in other mice bearing different mutations on STIM1. At present, no valid treatment is available for these patients. In the present contribution, we report that CIC-39Na, a store-operated Ca2+-entry inhibitor, restores platelet number and counteracts the abnormal bleeding that characterizes these mice. Subtle differences in thrombopoiesis were observed in STIM1 p.I115F mice, but the main difference between wild-type and STIM1 p.I115F mice was in platelet clearance and in the levels of platelet cytosolic basal Ca2+. Both were restored on treatment of animals with CIC-39Na. This finding paves the way to a pharmacological treatment strategy for thrombocytopenia in tubular aggregate myopathy patients.
引用
- Cordero-Sanchez C, Pessolano E, Riva B, et al. CIC-39Na reverses the thrombocytopenia that characterizes tubular aggregate myopathy. Blood Adv. 2022. PMID: 35696753. doi:10.1182/bloodadvances.2021006378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。